METiS Therapeutics Debuts on HKEX with 173% Surge, Raising Over HK$2.1 Billion in 2026's Largest Biotech IPO
METiS TechBio
AI-Driven Drug Formulation Developer
5Month13Day (Today), METiS TechBioTechnologyOfficially on the Hong Kong Stock ExchangeListingListed,Become GlobalThe First AI Drug Delivery Stock, and Also the First AI Large Molecule Biopharmaceutical Stock in Hong Kong.
On the first day of listing, METiS TechBioTechOpening ReportHK$28.68, UpperUp 173.14%,Total market value approximately HKD 33.054 billion.
This time, METiS TechBioFundraising Exceeds21HKD billion,Set a recordThe Largest IPO Fundraising in Hong Kong's Healthcare Sector Since 2026.
AsGlobally Leading AI Driving Nanomedicine Delivery Enterprises,METiS TechBioPharmaceutical Industry“SpaceX”With the goal of, independently developedThe World's FirstAINano-Delivery PlatformNanoForge，At the same time, it is alsoThe Only One in the World to Achieve8IndividualCompany for Precise Organ Targeted Delivery。
METiS TechBio has collaborated globally30Cooperates with top pharmaceutical and biotech institutions in China.2025Annual Company RevenueAchieve1.05100 million yuan,Increased by nearly70Times, with outstanding commercial growth potential.
At the listing ceremony,Dr. Caida Lai, Co-founder, Chairman and CEO of METiS TechBio, said:
"The future of biomedicine will no longer be just 'taking medicine when sick.' METiS TechBio's ambition is to use AI to build nano-rockets, achieving precise navigation within the inner space of the human body’s 30 trillion cells. By writing the code of nucleic acids and proteins into cells, we aim to reprogram diseased and aging cells into healthy ones. This is the original aspiration behind our entrepreneurship, and it is also the cause we will dedicate our entire lives to."。IPO is a new starting point for us to accelerate forward.，We will not辜负来自各界的支持和厚爱.”
Accompanying"Artificial Intelligence+"Biological economy, innovative drugs, and other national industrial policies continue to advance.AIThe pharmaceutical and drug delivery track is gradually entering a new stage of value implementation.
At the same time, METiS TechBio is entering a critical window period of accelerated pipeline release, expanded global cooperation, and continuous extension of the industrial ecosystem.
"Rocket+"Satellite" Strategy, Multiple Pipelines Accelerating Delivery
After successfully going public, the core logic supporting the long-term valuation of METiS TechBio,Ultimately, it will still come back to a key issue.
ItsNanoForgeCan the platform continue to produceInnovative assets with clinical and commercial value, further leading to more industry collaborations and licensing deals.
Since its inception, METiS TechBio has always been anchored “Rocket+Satellite”Core Strategy。"Rocket" RepresentativeAIThe capability of the driven nanodelivery platform; "satellite" refers to the innovative drug pipeline continuously incubated based on the platform.
The most noteworthy value of METiS TechBio now lies in its platform capabilities, which have begun to gradually enter the realization phase.
Current Layout of METiS TechBioUltra10Innovative pipeline,1Item inpre-NDAPhase,3PaymentCandidate Drug Enters Clinical Stage，4The drug is in the preclinical stage., covering multiple directions such as oncology, immunology, and metabolism.
CompanyDrug DevelopmentIn China,MTS-004Already inPre-market Application (pre-NDA) Key Stage, with a high degree of commercial certainty.
MTS-004Is a treatment forPseudobulbar Affect (PBA`, commonly known as`“Pseudobulbar affect”） An oral new candidate drug, which is not only the first one completed in ChinaⅢPhase Clinical TrialsAIEmpowering new drug formulations, it is also currently the only one in China.PBATherapeutic Drugs。
InMETiS TechBio's self-developedAINano Delivery PlatformNanoForgeEmpowered by,MTS-004Only use3months to complete what traditionally requires1-2Years of preclinical formulation development,From project initiation to completionⅢPhase Clinical Trials Only Took38Months。
Data shows that by2035In ChinaPBAPharmaceutical Market ForecastWill reach70Million yuan. Under the first-mover advantage,MTS-004HopefulCapture a significant market share。
At the same time,MTS-004The range of potential indications is also worth noting. Fan Dongsheng, an authoritative expert in ALS and neurological diseases in China, stated in relevant clinical studies,MTS-004Not only forPBASymptoms have shown significant improvement, while also demonstrating a positive trend in alleviating patients' swallowing difficulties.
This means that the potential beneficiary population of this product may further expand in the future.
It is worth noting that,MTS-004Completed Outward Licensing Collaboration, Upfront Payment1100 million yuan。METiS TechBioPossessProfit-sharing rights after subsequent listing,Expected to achieve"Down Payment+Milestone Payment+Long-term Sales SplitThe multi-layered revenue structure.
In addition to this, the successful listing on the Hong Kong Stock Exchange this time,Will be further enhancedMETiS TechBioSubsequent pipeline advancement capability.
Particularly noteworthy is that METiS TechBioIn Vivo Tumor ImmunotherapyDirection, multiple globally groundbreaking explorations have been conducted.
One of the core pipelinesMTS-105, mainly targeting liver cancer and advanced solid tumors with liver metastasis,Becoming the world's first to enter the clinical stagemRNACodingTCE（TCell Connector) Solid Tumor Therapy.
Currently,TCEIs rapidly becoming the nextPD-1、ADCLater, another important track in the field of tumor immunology that has received much attention, Amgen, Roche, Johnson & Johnson,ModernaGlobal pharmaceutical giants have all accelerated their layout.
While METiS TechBio has chosen a more cutting-edge approach.mRNAEncodingTCERoute.Compared with traditional proteinsTCEandCAR-TTherapy,mRNACodingTCEWithout the need for complex in vitro cell preparation processes, it offers advantages such as more convenient administration and higher production efficiency.，AndInEffect, safety, and side effect control, also show greater potential.
Data shows,MTS105Demonstrated Disruptive Advantages in Preclinical Studies，Each mouse was used only once.0.3–0.5 ugThe dose can achieve100%Complete Tumor Clearance。And the drug not only hasStronger Liver-Targeted Expression Effect, and has good safety.
Currently, this therapy hasInIITStage，And obtain the United StatesFDAOrphan Drug Designation,Opened a new chapter in the immunotherapy of solid tumors.
Another HeavyweightTCEPipelineMTS-109，Also inIITClinical Stage。
Compared with traditionalTCEDifferent,MTS-109Adopted ismRNATri-specificity of CodingTCEDesign. In animal experiments, it can achieve systemic effects at extremely low doses.BThe efficient clearance of cells demonstrates the significant potential of next-generation in vivo immunotherapy.
More crucially, this therapy has broad potential for expanding its range of indications. On one hand, it holds promise for application in autoimmune diseases such as lupus erythematosus and lupus nephritis; on the other hand, it can also cover conditions like lymphoma and multiple myeloma.BCell-associated hematological tumors.
This means that METiS TechBio is not only attempting single drug development but also building a more scalable next-generation treatment system around an in vivo immunotherapy platform.
In addition,METiS TechBio Has Significant Layout in the Metabolic Field，MTS-201Has currently enteredIPhase of clinical stage.
MTS-201TheSpecialThe difference is that it is the only one that has entered the clinical stage and has been proven to stimulateGLP-2OralTGR5Agonist.
Relying on a unique gut-targeting mechanism,MTS-201Not only has the potential for weight loss and blood sugar reduction, but also can improve fatty liver (MASH) and promote intestinal repair, showing application prospects for diseases such as short bowel syndrome. Compared with current metabolic therapies that heavily rely on injections,MTS-201Oral administration has obvious advantages in terms of patient compliance, safety, and side effect control.
In summary, METiS TechBio has entered popular fields such as immunology, oncology, and metabolism, but has avoided the homogenization and internal competition of single-target approaches, precisely positioning itself.TGR5 Agonist,mRNA-TCE Frontier differentiated directions such as solid tumor immunotherapy.
The core logic behind it is also very clear.，ThroughAI+Nano DeliveryTechnologySystem, seeking problems that traditional therapies have yet to truly solve.
Global Capital Consensus, LeadingAIDrug Delivery
Public information shows that thisIPOTotal18Cornerstone investors participate in the subscription,Total subscription amount approximately1.48Billion US dollars, accounting for a high proportion of the issued shares54.84%。
Whether it is the number of participating institutions, the degree of diversification of the investor structure, or the overall subscription ratio, all have reached record highs in the Hong Kong stock market in recent years.AIPharmaceuticalsBest in FieldLevel.
The world's largest asset management giant, BlackRockIn5000Million USD Leads，At the same timeUBS、Future Assets、OlympusSimilarly, international long-term funds have heavily participated.
As for domestic institutions, leading public offering institutions such as China Asset Management, Fullgoal Fund, ICBC Credit Suisse Fund, and Guangfa Fund have collectively entered the market with the same shareholding ratio, which is remarkable in Hong Kong's innovative drug sector.IPOChinaExtremely rare。
More notably, national-level funds have also made their first official move.AIPharmaceutical direction. Guoxin's GF Venture Innovation Investment Fund subscribed to METiS TechBio this time.3.71%Equity。CurrentAIAs innovative drugs have gradually become a core direction of global technological competition, the entry of national capital has further strengthened long-term confidence in the industry across the entire sector.
This shows that institutions both in China and overseas have effectively reached a consensus:Compared to molecular design, drug delivery has become the more critical bottleneck technology for innovative drugs.
In the past few decades, innovative drugs have been transitioning from simple chemical drugs to more complex biologics, including monoclonal antibodies, bispecific antibodies, peptides,ADC、mRNA、CRA-T......
The more complex the drug, the more difficult it is to stabilize its efficacy, thus relying more on precise and efficient delivery systems.
And this is also opening a brand-new era of treatment. In the past, many..."Diseases that are 'untreatable' or 'difficult to treat' have long lacked breakthroughs not only because of the absence of effective drugs, but more importantly, due to the lack of ability to truly deliver drugs to target tissues."
However, There have been several significant issues with traditional delivery systems over the long term.，Long R&D cycle and high cost,Many delivery solutions can only adapt to a certain type of drug, making it difficult to form true platform-based capabilities.
At the same time, core global delivery technologies and patents have long been concentrated in the hands of overseas research institutions and multinational pharmaceutical companies. This has also made delivery technology one of the key underlying issues in the development of China's innovative drug industry.
This direction is increasingly entering the strategic vision of the country.
Especially against the backdrop of escalating global technological competition, biomedicine is regarded as a crucial high ground for future industries.AIDelivery platforms and other underlying capabilities are becoming an important part of the industry's self-reliance and controllability.
"The Fifteenth Five-Year Plan for National Economic and Social Development of the People's Republic of China"This top-level design,ClarifiedDigital China Construction, Artificial Intelligence Technology Empowerment, Biomedicine andBiomanufacturingStrategic Direction for Industrial Development.
Therefore, in recent years, ChinaDrugThe support for the biomedical basic platform is also continuously increasing.
METiS TechBio has previously collaborated with the National Center for Nanoscience and Technology to jointly establish"Drug Delivery Nanocarrier Laboratory", and was approved2025Annual Key Laboratory of Beijing. Notably, in the same year269Among the approved key laboratories in China, this laboratory is also the only one focusing on "artificial intelligence+"Biomedical" Cross-Innovation DirectionPlatform。
And the core behind this is METiS TechBio's long-term development.NanoForgePlatform。The technical foundation lies in,METiS TechBio has built a universal typeAINano DeliveryAnd drug developmentPlatform, paving a development path with more room for imagination.
The platformIntegrationFinishedQuantum Chemistry,AILipidsLarge Model, Dry and Wet LabsTechnology, for small molecules,mRNA、siRNA and other different types of drugs, toAndLiver, lungs, heart, muscles, tumors, immune system, central nervous system, gastrointestinal tract, etc.8IndividualDifferent Target Organs, quickly generate the optimalResearch and Development as well asDelivery Solution.
ThisUnder the Drive of Technology, willDevelopment of TargetedLNPThe average time for small molecule formulations has been compressed from several years to2-3Months,Furthermore, it breaks the limitations of drug types and targeted organs, with the capability to coverGeneralThe Potential of Drug Delivery.
This differentiated positioning has enabled METiS TechBio to摆脱了同质化竞争，站在了产业生态的上游，为后续商业拓展奠定了不可替代的技术地位。
And with the completion of the IPO, the capital, brand, and globalization resources brought by the capital market are expected to further push the company's business ecosystem and technology system into a new cycle phase.
On the one hand, the company can leverage its capital strength and industry influence after going public to further expand its global cooperation footprint, attracting more pharmaceutical companies, biotech firms, and research institutions into the ecosystem.
On the other hand, more collaboration scenarios also mean the accumulation of more real R&D data.，And can also push in reverseAIModel training, lipid library optimization, and delivery system iteration.
Thus, METiS TechBioFinal Formation"Technology Iteration - Commercial Application - Data Feedback"Continuous Closed-loop，This is alsoCompanyThe long-term value worth paying attention to.
In conclusion
METiS TechBio has always defined itself as"Pharmaceutical IndustrySpaceX”，This highly technological analogy makes it difficult for many pharmaceutical industry practitioners to intuitively understand its deeper implications.
METiS TechBio is analogous to"Pharmaceutical IndustrySpaceX”，It is not just that both rely on dedicated carrier systems to achieve space transportation and precise delivery of cellular drugs, respectively.
The true core commonality between the two lies in:Trying to reconstruct traditional complex industries with high costs and strong experience dependence into a new industrial model that can be engineered and scaled.
SpaceXWhat they do is through reusable rockets, vertical integration, autonomous manufacturing, and rapid iterative testing,Breaking the High in AerospaceHigh, the low-frequency industry status quo, significantly lower the threshold for aerospace entry, and open up a vast commercial aerospace market.
METiS TechBioThroughLong-term layout of nano-delivery,AILipid Large ModelAnd AutomationDry and WetExperimental capabilities, in essence, are precisely about trying to establish such a set of fundamental abilities.，Lower the threshold for drug delivery, enabling patients to access higher-quality and more affordable medications.
And the listing practice of METiS TechBio is preciselyAIA Model for the Development of the Pharmaceutical Industry.
AIIt has long surpassed the attributes of traditional R&D tools, upgrading empirical R&D to a predictable engineering paradigm, spanning the entire process of target discovery, delivery system development, and clinical trials, achieving industrial efficiency improvement and cost reduction.
In the future, as more companies like METiS TechBio come to the forefront, AI pharmaceuticals will no longer be an emerging concept label, but a decisive force in promoting human health and breaking through the boundaries of innovative drug research and development.
Warm Tips
